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C. Matijssena, G. K. Kinsellab, G. W. Watsona and I. Rozasa*
The a1-adrenoceptor is a target for the treatment of several conditions from hypertension to benign prostatic
hyperplasia. In this paper, we describe a new analysis approach to explore the conformational space of several
ligands of the a1-adrenoceptor and we also present the calculation of their proton affinity and basicity. For each
compound a conformational search followed by a semi-empirical optimisation was performed and a selection of
conformations for each ligand was subjected to further optimisation using density functional theory methods.
Different positions were explored to determine the favoured site of protonation, and then, the proton affinity (in the
gas phase) and basicity (using the polarisable continuum model for the aqueous solution) were calculated for each of
them. In addition, an alternative method using one explicit water molecule in combination with the polarisable
continuum model for aqueous solvent was explored. Moreover, the acid dissociation constant (pKa) in water of these
26 compounds was calculated because this is an important parameter for a ligand when binding to its receptor. The
experimental pKa values of six of these ligands and those of two compounds with a very low and a very large pKa were
used to validate the theoretical methodology. Copyright © 2011 John Wiley & Sons, Ltd.
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INTRODUCTION
Drugs interact with their receptor in an aqueous environment
and at physiological pH. Therefore, their protonation state plays
an important role in the interaction between the ligand and
the receptor. In particular, looking at drugs that interact with
a1-adrenoceptors (a1-ARs), which are G protein coupled receptors
(GPCRs) involved in several diseases and conditions,[1] it has
been found that a protonated N atom plays an important role in
the binding of the ligands to a particular a1-AR subtype (a1A-AR).
This protonated N has become a common feature in several
pharmacophore models;[2–5] and thus, in docking studies, it has
been shown that an aspartic acid (conserved amongst most of
the GPCRs) can interact with this protonated functional group.[6]
The preference for each N atom to be protonated can be
determined by calculating the corresponding basicity (i.e. proton
affinity in the gas phase –PA-). Techniques such as electrospray
ionization, matrix-assisted laser desorption or the extended
kinetic method allow for the experimental determination of
PA;[7,8] however, basicities can also be determined using
computational methods. To obtain accurate PA values in the
gas phase, or basicities (B) in solvation, the bioactive or, when
this is not known, some of the most stable conformers for each
compound should be considered. Hence, a conformational
search can be performed followed by a thorough optimisation
of a large number of possible conformations. This step is time
consuming and often simplified by limiting the number of
conformations that are optimised. However, the correct minimum
energy conformation should contribute to a better description
of molecular properties participating in the ligand–receptor
interactions and, for that reason, we have chosen an approach that
selects a number of low energy conformations based on ligand
structural flexibility and allows further refinement of each
conformation. From the collection of optimised conformers, the
minimum energy conformation can be selected. This minimum
energy structure can then be used for PA/B determination
searching for the most favourable N atom to be protonated.
Using density functional theory (DFT) methods, Alkorta et al.
have previously studied the basicity of a number of hydrogen
bonded complexes between halogen acids and different
bases,[9] and that of different triple bonded molecules formed
by C, N, Si, P, B and Al.[10] Also, Alkorta and colleagues have
calculated the PA of different series of hydrocarbons,[11]
triazoles,[12] and small molecules.[13] Moreover, Dmitrenko et al.
obtained PAs within 3–5 kcalmol–1 of the experimental values
in a series of small molecules (enolate intermediates and
phosphine complexes).[14,15] To mimic the solvent, different
approaches can be used but we have previously found that
the use of the polarisable continuum model (PCM) produces
good results.[16,17]
Thus, using the energy of the minimum energy conformation,
the PA (enthalpies in the gas phase) or the basicity (free energies
in the solvated phase, PCM) for each of the N atoms can be
determined using formula (1) or (2) respectively
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gas phaseð ÞPA ¼ Eprotonated  Eunprotonated (1)
PCMð ÞB ¼ Eprotonated  Eunprotonated  E Hþð Þ (2)
where Eprotonated/Eunprotonated are the energies of the protonated
and unprotonated species (enthalpies in the gas phase or free
energies in the PCM), E(H+) would be null in gas phase, but in
the PCM is the solvation free energy of the proton [ΔG0solv(H
+)],
which has been experimentally determined in water as 265.9
kcalmol–1.[18,19]
As mentioned before, the basicity and hence the pKa plays an
important role in the pharmacokinetic profile of a potential drug.
The experimental evaluation of the pKa of a compound is not
always possible and can be tedious. However, the pKa in water
can also be determined using a computational approach based
on the thermodynamic cycle shown in Fig. 1. [7,20–22]
After calculation of the minimum energy of the molecule in
the different protonation states, the pKa in water can then be
derived from this thermodynamic cycle using formula (3)
pKa ¼
ΔG0aq
2:303 RT (3)
where ΔG0aq is the aqueous solvation free energy, R is the
universal gas constant and T is the temperature (298 K). ΔG0aq
can be calculated using formula (4)
ΔG0aq ¼ ΔG0gas  ΔG0solv AHþð Þ þ ΔG0solv Að Þ þ ΔG0solv Hþð Þ (4)
The ΔG0solv(A) and ΔG
0
solv(AH
+) terms can be obtained from our
calculations by subtracting the gas-phase free energy from the
PCM free energy. The ΔG0solv(H
+) term, as mentioned before, is
a known experimental value.[13,14] The ΔG0gas term can be
obtained using formula (5)
ΔG0gas ¼ G0gas Að Þ þ G0gas Hþð Þ  G0gas AHþð Þ (5)
where G0gas(AH
+) and G0gas(A) are the free energy of the protonated
and unprotonated states respectively. G0gas(H
+) is the free energy of
the proton and can be calculated using the Sackur–Tetrode
equation resulting in6.28 kcalmol–1.[23] Hence, knowing the free
energy of all the solvated species (A and AH+) calculated with PCM
we can calculate ΔG0aq and determine the pKa of the compounds.
Therefore, the aim of this study is to explore the conformational
space of several a1-AR’s ligands and to theoretically calculate their
PA, basicity and pKa to determine their optimal protonated state
for future molecular modelling and docking studies.
METHODS
The agonists adrenaline and noradrenaline and a selection of
a1-AR antagonists taken from the literature
[2] resulted in a set
of 26 compounds (Fig. 2) covering a wide range of binding
affinities for the different a1-ARs subtypes. Considering that the
experimental pKa value of adrenaline (1),
[24] noradrenaline
(2),[25] prazosin (3),[26] alfuzosin (4),[27] doxazosin (5)[28] and
terazosin (6)[29] are already known, these compounds will serve
as a validation set for the determination of the computational
pKa values presented here.
These compounds were subdivided into six different groups
based on common scaffolds (Fig. 3) and thus, this common substruc-
ture will be used to derive the site of protonation for similar ligands.
To explore the conformational space of these molecules, a
random search using the Monte Carlo method was performed
with SYBYL (version 7.2, Tripos International, St. Louis, MO,
USA)[30] applying the conjugate gradient minimisation method,
a maximum number of iterations of 1000, a gradient of 0.0005,
the Tripos force-field and Gasteiger–Hückel charges. This confor-
mational search produced 200–1500 different conformations for
each compound. Each conformer was further optimised using
GAUSSIAN03 (Gaussian, Inc., Wallingford, CT, USA)[31] with the AM1
semi-empirical method, and the energy and various dihedral
angles were used to select different conformations.
Taking into account the number of dihedral angles that could
account for molecule flexibility, two different approaches were
used to select the most representative conformations for further
optimisation: (i) in the case of molecules with ≤5 rotatable
bonds, the corresponding dihedrals of each possible pair of
rotatable bonds were plotted against each other. Considering
that each rotatable bond of the AM1-optimised structures
produced two, four, six or eight possible dihedral angles,
different clusters were formed. From each cluster the lowest
energy conformation was selected; (ii) in the case of molecules
with >5 rotatable bonds, an alternative approach was used.
Thus, the dihedral angle for each rotatable bond was plotted
against the conformer’s energy and in that way several clusters
of two to eight angles were formed. From each cluster the
conformation with the lowest energy was selected.
Using either of these methods for the selection of low energy
conformations produced a smaller set of 10–25 conformations
per compound. Each of these AM1 conformations was further
optimised with GAUSSIAN03 using the Becke 3-Parameter
(Exchange), Lee, Yang and Parr (B3LYP) hybrid method with the
6-31G* basis set. From the different optimised conformers, that
with the lowest electronic energy was selected.
To determine the PA, each of the N atoms of each structure
was individually protonated. Optimisation of the neutral and
the different protonated conformations was performed using
B3LYP/6-31G* level of theory in the gas phase and in the PCM
solvent model. Additionally, vibrational frequency calculations
were performed at the B3LYP/6-31G* level, to characterise the
stationary points as minima. The variation in zero-point energies
(ZPE) and thermal corrections from zero degree to 298 K have
been considered in the calculations. No scaling factor for the
ZPE values was taken into account.
An alternative strategy to account for the solvation effects was
pursued by adding one explicit water molecule[32,33] interacting
through hydrogen bonds (HBs) with the structures considered
(Fig. 4). We considered that an explicit water molecule would have
a different effect on the compounds than a continuous solvation
model such as PCM. Thus, we explored if different minimum
energy conformations were found and, perhaps, more accurate
pKa values. For the unprotonated state of each molecule, the H
atom of the water molecule was orientated towards each of the
G0gas
+ (gas) + (gas)
G0solv (AH + ) G0solv (A) G0solv (H + )
AH
AH+  (aq)                     
A (gas) + H
A (aq) + H+  (aq)  
G0aq
Figure 1. Thermodynamic cycle of a compound in gas and solvent
states describing the energy terms which arise from the change from
one state to another.
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Figure 2. Structures of the 26 compounds studied in this work.
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N atoms at an initial distance of 2.0 Å. For the protonated form, the
O atom of the water molecule was orientated towards the H atom
protonating each N atom with a distance of 1.8 Ǻ between both
atoms as the starting point for the optimisation.
The computation of the ligands with an explicit water
molecule in the gas phase and PCM will help to decide if such
‘supermolecule’ (ligand+H2O) facilitates the computation of
PA and basicity or, on the contrary, will not provide a better
description only adding more computational time.
RESULTS AND DISCUSSION
Determination of proton affinities and basicities
The PA for each compound was calculated as the difference in
enthalpy between the neutral and protonated species in the
gas phase Eqn (1) whereas when using aqueous salvation, the
basicities were calculated using the free energies including
the solvation energy of the proton Eqn (2). The natural agonists
adrenaline (1) and noradrenaline (2) only have one N atom that
can be protonated; therefore, only one PA/B for each of the
structures was calculated (Table 1). Comparing the 298 K
thermally corrected structures with the uncorrected ones, both
in the gas phase and the PCM solvent optimised structures, a
decrease of the PAs (~9 kcalmol–1) is observed. The difference
between the gas phase optimisations and PCM optimisations is
~213 kcalmol–1 for adrenaline and ~209 kcalmol–1 for noradrena-
line. These differences account for the solvation of the proton
(265.9 kcalmol–1) and other interactions that the molecule and
the proton will establish with the environment in the aqueous
solution model.
The results for Group 2 (compounds 3 to 9) are shown in
Table 2. A similar PA/B pattern is observed for all the compounds
within this set and the previous one, with the Nc atom being
favoured for protonation. Nitrogen Ne, in compounds 3–7 and
9, belongs to an amide group and, therefore, would not be likely
protonated; while Na is an ’aniline’ type of amine and it would
require very acidic conditions to be protonated. Accordingly,
the PA/B values obtained for those N atoms were very low and
are omitted from the table. Again the basicities (PCM results
in aqueous soluition) are smaller than the gas phase PA. In
articular, the B thermally corrected values obtained for Nd are
so small (even negative in the case of compound 4) that it seems
to indicate that this N would not be protonated at physiological
conditions. Interestingly, Nd is not part of a six-membered ring
(piperazine or piperidine) only in compound 4.
All compounds in Group 3 (10 to 15), which are favourably
protonated at Nb in the gas phase (Table 3), have a N atom as
part of an amide group (Nd) and because this type of N atom is
rarely protonated the PA/Bs obtained were very low and they
Group 1 Group 2
Group 3 Group 4 
Group 6Group 5
Figure 3. Different scaffolds considered: Group 1 (compounds 1 and 2), Group 2 (compounds 3 to 9), Group 3 (compounds 10 to 15), Group 4
(compounds 16 to 18), Group 5 (compounds 19 to 23) and Group 6 (compounds 24 to 26). The N atoms to be protonated are indicated with subindex
letters for each group.
Figure 4. Examples of water molecule orientation and initial distance
used (in Å) in the complexes with the neutral (left) and protonated states
(right).
Table 1. Calculated proton affinities and basicities (kcalmol–1)
of Group 1 compounds
Gas phase PCM (water)
Nitrogen PA
(0K)
PA
(298 K)
B
(0 K)
B
(298 K)
Adrenaline (1) Na 241.5 232.5 28.2 19.5
Noradrenaline (2) Na 236.4 227.5 27.6 18.6
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are not shown in the table. The Nb position corresponds to a
piperazine N atom attached to an aliphatic chain. Compound
11, which is the only derivative with a methyl branch in the
aliphatic chain, seems to have a different PA/B pattern with
slightly lower values than the rest of the compounds in the set.
Compound 15 has another amino group, Nc, which is an aniline
type of nitrogen, which could explain the negative thermally
corrected B value obtained (see Table 3).
Compounds in Group 4 (16–18) show a consistent preference
of protonation at nitrogen Na in both the gas phase and aqueous
PCM (Table 4). Compound 16 has other N atoms but differences
larger than 20 kcalmol–1 are observed in favour of nitrogen Na,
which seems logical considering that Nb and Nc are involved in
an imidazoline ring. Compound 17 has only one N atom that
can be protonated. In compound 18, the Nc belongs to an indole
system and therefore is too acidic to be likely protonated
(data not included in Table 4). Despite the limited number of
compounds in this group and only two of them having multiple
N atoms to be protonated, the large difference in PA/B observed
indicates that nitrogen Na is the one that will be protonated.
Compounds in Group 5 (19–23) show consistent results both
in gas phase and PCM, all of them showing a preference for
protonation at nitrogen Na (Table 5). Compounds 19, 21 and
23 have only one N atom that can be protonated. Compound
22 has two N atoms but Nb belongs to an indole system, hence,
it is too acidic to be protonated. In the case of compound 20, a
large difference favouring protonation on Na over Nb (with a
certain indole-like nature) is observed and Nc (amide) is too
acidic to be likely protonated, for that reason the corresponding
results are not included in the table.
The structures in Group 6 (24–26) show consistent results in
both gas phase and PCM with a preference for protonation on
the Na atom (Table 6). In compound 24, there is a large
difference in PA/B between nitrogen Na and other N atoms
(amide and aniline type); hence, nitrogen Na is the preferred site
for protonation. Nitrogen atom Nb belongs to an amide group
(in 24 and 25) and Nd belongs to an indole ring (in 26), hence
they are too acidic to be protonated.
The values of the PA/Bs obtained in each group of ligands
have allowed us to identify which N atom is most likely to be
protonated. Our results show that, in structurally similar
compounds, as expected, the same N atom is preferred for
protonation, which is useful when modelling the receptor–
molecule interaction in series of similar compounds.
Modelling the solvent with the addition of an explicit
molecule of water
An alternative approach for the calculation of basicities in solvated
molecules was taken by introducing a properly orientated water
Table 2. Calculated proton affinities and basicities (kcalmol–1) ofGroup 2 compounds
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molecule interacting with a selection of compounds from our set,
and performing calculations at the B3LYP/6-31G* level in gas
phase and with the PCM aqueous solvation. Considering that
water molecules can form HBs with any of the N or NH groups
present in these molecules, this study was performed to
investigate if explicit water molecules can provide a more realistic
picture for the solvation influencing the calculated PA/B values.
The molecules chosen for this study were: (i) both agonists
(1 and 2); (ii) a representative of each Group (2 to 6) (compounds
6, 13, 16, 22 and 24); (iii) a conformationally restricted compound
(17); and (iv) a compound with a unique site for protonation (23).
The results presented in Table 7 show similar results with and
without an explicit water molecule, and in all cases the same N
atom (usually belonging to a piperidine/piperazine ring or within
an aliphatic chain) is preferably protonated.
Inclusion of an explicit water molecule results, as expected, in
larger basicities, with an increment of ~7 kcalmol–1 in the gas
phase and ~5 kcalmol–1 in the PCM water solvation. In general,
the effect of the addition of the water molecule seems to be
independent on the compound studied. Our results indicate that
the influence of an explicit water molecule confirms the findings
obtained with the PCM solvation model alone and, clearly, this
added water molecule provides extra stabilization to the
protonated system helping provide a better description of the
protonation state of these a1-AR ligands. However, taking into
account computational time issues, we can conclude that the
Table 3. Calculated proton affinities and basicities (kcalmol–1) of Group 3 compounds
Table 4. Calculated proton affinities and basicities (kcalmol–1) of Group 4 compounds
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Table 5. Calculated proton affinities and basicities (kcalmol–1) of Group 5 compound
Table 6. Calculated proton affinities and basicities (kcalmol–1) ofGroup 6 compounds
Table 7. Calculated proton affinities and basicities (kcalmol–1) using an explicit
water molecule
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use of the PCM alone is enough to achieve a good description of
such protonated species.
Determination of the pKa of the compounds studied
The basicity of the ligands and their pKa are critical when analyzing
ligand–receptor interactions because basicity determines the in-
teraction with the receptor and the pharmacokinetic properties of
the ligand. Considering that the overall proportion of nonionizable/
ionizable compounds for drug-like substances is not well known,
Manallack reviewed the literature with regard to both the propor-
tion of ionizable substances and pKa distributions.
[34] However,
the experimental determination of the pKa is not always straightfor-
ward and there are computational alternatives to predict this
parameter. Several commercial packages include an option to eval-
uate pKa; however, these packages work as a black box and the
methodology used is not always clearly explained. Our approach
involves applying the thermodynamic cycle presented in Fig. 1. To
validate this theoretical approach, we have computed, first, the
pKa values of a number of compounds for which an experimental
pKa had been previously determined (Table 8). These compounds
include adrenaline (1), noradrenaline (2) and compounds 3 to 6,
which are currently commercially available a1-adrenoceptor
antagonists and, hence, their pKa values are in agreement with
the pharmacokinetic properties required for an actual drug.
However, because these six values fall within a narrow range (see
Table 8), we have also calculated the pKa value of two compounds,
debrisoquin and phenothiazine (Fig. 5), where experimental pKa
values are very large (11.9 [35]) and very small (2.9[35]), respectively.
Debrisoquin is an antihypertensive drug and phenothiazine is
present in different neuroleptic and antihistaminic drugs, such as
chlorpromazine and promethazine, respectively. These compounds,
even though not related to our data set in terms of biological
activity, can expand the scope of the computational method
because of the extreme pKa values that they exhibit.
In the case of debrisoquin, the results (Table 8) are in
agreement with the experimental pKa showing that the
guanidine moiety [NH2–C(=NH)–N–] is a very strong base. This
is well known, because guanidine itself is a very strong base in
water (exp. pKa =13.6).
[36] Regarding phenothiazine, the small
calculated pKa (Table 8) indicates that the amino group in this
compound is weakly basic. Therefore, even though a very large
value was calculated for debrisoquin and a very low one was
computed for phenothiazine, large deviations from the
experimental pKa were obtained. However, for those values in
the middle range, in general, the computed pKa were slightly
larger than the experimental ones but they are more or less
within the experimental range (see graph in Fig. 5).
Considering that using this theoretical method, acceptable
pKa values were obtained for the compounds with values in
the middle range, the pKa value of all the compounds in the
dataset was determined in a similar manner. The results (Table 9)
indicate that the compounds will be mostly protonated at
physiological pH, with most compounds showing pKa values
larger than 7.
In Group 2, the pKa of most of the compounds are within a 7.9
to 9.0 range, except for compounds 8 and 9, which pKa are >10
(Table 9). This can be explained because these two compounds
contain a quinoline core instead of a quinazoline core, which is
present in the other compounds of the group (3–7). The pKa of
quinoline (4.85[37]) is known to be larger than that of quinazoline
(3.31[29]). Moreover, the pKa of pyridine, which is larger than that
of pyrimidine (5.14 and 1.10, respectively[29]), becomes even
larger with a NH2 group in para (9.17 for 4-aminopyridine
[38] vs
5.71 for 4-aminopyrimidine[39]), and all the compounds in this
Group 2 have an amino functionality in position 4 of the
quinoline/quinazoline cores.
Regarding Group 3, most of the pKa values obtained (Table 9)
are consistent with this type of N,N’-arylalkylpiperazines. The
pKa value of 1-phenylpiperazine is 6.30 and the average pKa
values for a number of 1-arylpiperazines such as ofloxacin,
enoxacin, norfloxacin, ciprofloxacin or pipemidic acid is around
5.6.[40] To explain the low pKa values of 10, 11 and 15, it should
be considered that, when protonated in the piperazine N-alkyl
Table 8. Experimental and computational pKa values
obtained for compounds 1 to 6 and for reference com-
pounds debrisoquin and phenothiazine
Experimental pKa Computational pKa
1 8.6[24] 9.7
2 8.6[25] 9.0
3 7.0[26] 8.8
4 8.1[27] 8.3
5 6.9[28] 7.9
6 7.1[29] 8.1
Debrisoquin 11.9[35] 20.6
Phenothiazine 2.5[35] 5.9
Figure 5. Structure of debrisoquin (left, top) and phenothiazine (left, down) and comparison between experimental (blue) and theoretical (red)
pKa values.
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position, they are able to form intramolecular HBs with the O
atom of an amide group connected by an ethylene linker
(10 in Fig. 6, and 11) or with the p system of a double bond[41]
(15 in Fig. 6). This intramolecular HB could stabilise the
protonated species. Compounds 12, 13 and 14 (pKa ~7 or more)
in their protonated N–H+ form cannot establish such an HB
interaction (i.e. compound 12 in Fig. 5) and therefore their
protonated species are less stabilised.
Compounds 17 and 18, in Group 4, show pKa values around
7 or more (Table 9) in agreement with aliphatic tertiary
amines.[29] In the case of the N-substituted diphenylamine 16,
the pKa obtained is negative in agreement with the low
experimental values reported for diphenylamine itself (0.78),
N-methyldiphenylamine (1.71), 4-carboxydiphenylamine (1.24)
or 4-nitrodiphenylamine (2.78).[42]
The pKa obtained for compounds in Group 5, can be discussed
in three sets even though they all contain an aliphatic amine
(secondary or tertiary). Derivatives 19 and 21 both have two
OCH3 groups attached to the phenyl ring at the ortho positions
of the O-alkyl chain containing the amine to be protonated
(see Fig. 2). In both cases, an HB seems to be formed between
the NH group in the aliphatic chain and one of these OCH3 in
the neutral forms (d[O. . .H] for 19: 2.18 Å and for 21: 2.27 Å).
When the amino group is protonated, this HB becomes shorter
(d[O. . .H] for 19: 1.81 Å and for 21: 1.85 Å), stabilising the cationic
species and thus explaining the low pKa values obtained (see
Table 9). However, this HB is not formed in compounds 20 and
22 because of the large size of the substituents at the ortho
position of the aromatic ring (OCH2CF3 and OCH2–cyclopropane).
In the case of 23, the O-alkyl chain does not have OCH3 groups
in ortho positions in the phenyl ring; however, at the end of the
O-alkyl chain there is another aromatic ring containing an ortho
OCH3 group. The N atom to be protonated is a tertiary amine
and thus in the neutral form no HB can be form. When the tertiary
amine is protonated, though, an HB is formed between this NH+
group and the OCH3 of the nearest aromatic ring (d[O. . .H]:
1.91Å) forming a pseudo six-membered ring, stabilizing this
protonated species and justifying the very low pKa value computed.
Finally, the values obtained for the three compounds in Group
6, which are all N-alkylpiperidines, are in the range of experimental
pKa of related compounds such as 1-propylpiperidine (10.48
[29]).
In general, and considering the results found for debrisoquin
and phenothiazine (compounds with extreme pKa values), the
method seems to work properly only in the middle range (from
6 to 9 pKa units) and, thus, those computed values obtained
outside the middle range (compounds 8, 9, 11, 15, 16, 22, 23, 26)
should be considered only in qualitative terms.
Table 9. Calculated pKa values from the thermally corrected
B values of all the compounds studied here
Compound pKa Compound pKa
Group 1 Group 2
1 9.7 3 8.8
2 9.0 4 8.3
Group 3 5 7.9
10 6.3 6 8.1
11 4.2 7 9.0
12 7.6 8 11.8
13 6.7 9 12.2
14 8.0 Group 4
15 5.0 16 3.0
Group 5 17 6.8
19 6.2 18 9.7
20 9.9 Group 6
21 6.3 24 9.9
22 10.0 25 7.7
23 3.6 26 10.9
(a)  (b) 
(c) 
Figure 6. Optimised structures of the protonated forms of compounds (a) 10, (b) 15 and (c) 12, calculated at B3LYP/6-31 G* level with the PCM sol-
vation model approach, showing the possible HB formation (grey line) in the case of compounds 10 (between the N–H+ and a C=O of a ring) and 15
(between the N–H+ and a C=C of a ring), and the lack of such a HB in 12.
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CONCLUSIONS
We have performed an extensive conformational search and
optimisation to find the optimal minimum energy conformation
of a series of 26 a1-AR ligands (two agonists and 24 antagonists).
For each compound a conformational search followed by a semi-
empirical optimisation was carried out and then, for each
ligand, some of these conformations were subjected to further
optimisation using DFT methods.
The determination of the proton affinities and basicities of these
compounds shows in very few cases different results between op-
timisation in gas phase or using the PCM solvent model. Because
of the fact that compounds interacting with a receptor are nor-
mally in an aqueous environment, the basicity values obtained
(using the PCM) are of more biological interest than the PAs.
Consistent results are obtained regarding the preferred N atom
for protonation according to the PA/Bs within each group of com-
pounds. This suggests that when structurally similar compounds
are studied, their site for protonation can be determined by ex-
ploring only a small number of compounds within the set.
To improve the solvation model for our molecules, we have
studied the effect that an explicit water molecule would have
in the solvation effects. We have found that the addition of an
explicit water molecule to our models results in similar results for
PA and basicity. The same N atom was preferred for protonation
with or without the explicit water molecule. Therefore, this
approach, which is longer in computational time, does not provide
any improvement to the determination of PA and/or B.
The interaction between a drug and its receptor at physiological
pH is determined by the pKa of the drug. Thus, computational tools
that allow for the theoretical determination of the pKa have been
developed and, by using this type of approximation, we have com-
putationally evaluated the pKa values of our set of molecules and
those of two reference drugs (debrisoquin and phenothiazine)
with extreme pKa values (very large and very small pKa,
respectively). The results in this evaluation produced a very large
pKa for debrisoquin and a very small one for phenothiazine but
with very large deviations from the experimental values. However,
better agreement was found for those compounds with
experimental pKa values in the middle range (compounds 1 to
6). Hence, for those compounds with no experimental pKa values
available, the results obtained could be explained based on
similar derivatives reported in the literature. Even though the
approach seems to work better for pKa values in the middle range,
it can be used in a qualitative manner outside this range.
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